Special Issue "Non-Human Primate Model Suitable to Assess Efficacies of New Drugs and Vaccines"

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 86

Special Issue Editor

National Cancer Institute (NCI), Bethesda, MD, USA
Interests: non-human primate model (baboon); establishment of infections; vaccination; immune responses; immune cell isolation; immune cell characterization; serum isolation and antibody profile; parasite isolation from circulation

Special Issue Information

Dear Colleagues,

We are pleased to announce the launch of “Non-Human Primate Model to Assess Efficacies of New Drugs and Vaccines”, a Special Issue of the Vaccines journal by MDPI. This issue will publish original, peer-reviewed, science-based research articles that help to enhance the field of vaccine development for various infectious diseases using a non-human primate model. This issue will be supervised by editors from international academia to maintain a high standard and aims to primarily focus on non-human primate models for infectious diseases and how the efficacy of various drugs and vaccines can be assessed before human trials. Ultimately, the issue seeks to offer a forum for researchers where innovative research on vaccine and drug testing in non-human primate models can be expanded across the scientific community at large.

This Special Issue also invites reviews specifically focusing on drug and vaccine development in non-human primate models. Finally, we welcome scholars from relevant fields to contribute to this issue through their research articles or review papers for publication

Dr. Souvik Karmakar
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • non-human primate model
  • infectious diseases
  • vaccine development
  • characterization of immune responses and immune correlates of protection

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop